NCT03759340 - ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

September 11, 2019

Study Completion Date

September 11, 2019

Conditions

Alopecia AreataAlopecia UniversalisAlopecia Totalis

Interventions

DRUG

ATI 502 0.46% Topical Solution

apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)

Trial Locations (20)

10075

Aclaris Investigator Site, New York

14623

Aclaris Investigator Site, Rochester

24501

Aclaris Investigator Site, Lynchburg

29607

Aclaris Investigator Site, Greenville

30078

Aclaris Investigator Site, Snellville

33472

Aclaris Investigator Site, Boynton Beach

37215

Aclaris Investigational Site, Nashville

37922

Aclaris Investigator Site, Knoxville

48038

Aclaris Investigator Site, Clinton Township

48202

Aclaris Investigator SIte, Detroit

55432

Aclaris Investigator Site, Fridley

55455

Aclaris Investigator Site, Minneapolis

64506

Aclaris Investigator Site, Saint Joseph

68144

Aclaris Investigator Site, Omaha

72758

Aclaris Investigator Site, Rogers

77056

Aclaris Investigator Site, Houston

78745

Aclaris Investigational Site, Austin

80210

Aclaris Investigator Site, Denver

89148

Aclaris Investigator Site, Las Vegas

97223

Aclaris Investigator Site, Portland